Management team

David W Anderson – Chairman and CEO

Mr Anderson has been a successful entrepreneur in the orthopaedic medical device field for over 20 years. He has led four orthopaedic organizations; Osteotech (Executive VP), Bionx Implants (CEO), Replication Medical (Founder and Director), and Gentis (CEO). Mr. Anderson was a founder of Osteotech and was the founder and CEO of Bionx Implants which he grew through over 60 product approvals to over $20 million in sales in less than three years. He was also part of the team that created Integra LifeSciences and was an active member of the Board of Directors of Replication Medical. He has raised over $150 million in venture capital, taken a company through the IPO route onto NASDAQ, and has been a part of multiple M&A transactions.

Simon Coles – Vice President, Global Sales and Marketing

Mr Coles’ career spans two decades of consistent achievement in Healthcare Sales and Marketing, with Smith & Nephew and Baxter. He has launched medical devices that have pioneered new treatments in the fields of biosurgery, wound care, orthobiologics and tissue regeneration. Operating at a global level he has worked extensively throughout Europe, Asia and the United States. Mr. Coles was Head of US Marketing from 2002-2005, helping to build the Baxter Biosurgery business to $125million revenue. His other role at Baxter was as Head of Global Marketing and Strategy with the Baxter Biosurgery unit. During this period at Baxter he was a member of the senior management team that created a new, global, direct sales franchise in surgery, with revenues of $260million, growing at 22% per annum.

Howard Miller – Chief Financial Officer and Executive Director

Howard’s background is in life science finance and research. From 2000 to 2007, Howard was a Life Science Equity Analyst at UK broker Teather& Greenwood, becoming Head of Research in 2004. During this period, Howard worked on the flotation’s of a number of life science companies and provided equity research on UK listed large and small cap medical businesses. In 2007, Howard joined Oakes, Lyman & Co. Limited, working with their portfolio of private medical device companies, including CellCoTec, on financing and strategy. He was appointed Acting CFO of CellCoTec in 2009 and joined the company full time as Chief Financial Officer in 2010.

Joel Guidoux – Head of Regulatory and Clinical Affairs

Joël brings with him over 13 years of experience in international clinical development from the CRO (Innovex, Quintiles, PPD) and the Biotech (Genzyme) sectors, both with medicinal products and medical devices.
At Genzyme, Joël played an active role in the design and conduct of clinical trials leading to the registration of Synvisc One in Europe and the United-States, and subsequently worked in cartilage repair on a large European pivotal trial with autologous chondrocytes implantation.
Joël joined CellCoTec in August 2009 to take responsibility for clinical and global regulatory activities.